The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement

Metabolism: Clinical and Experimental

Volumn 71, Issue , 2017, Pages 17-32

  Athyros, Vasilios G ^a   Alexandrides, Theodore K ^b   Bilianou, Helen ^c   Cholongitas, Evangelos ^a   Doumas, Michael ^a   Ganotakis, Emmanuel S ^d   Goudevenos, John ^e   Elisaf, Moses S ^f   Germanidis, Georgios ^a   Giouleme, Olga ^a   Karagiannis, Asterios ^a   Karvounis, Charalambos ^g   Katsiki, Niki ^a   Kotsis, Vasilios ^g   Kountouras, Jannis ^a   Liberopoulos, Evangelos ^f   Pitsavos, Christos ^h   Polyzos, Stergios ^a   Rallidis, Loukianos S ⁱ   Richter, Dimitrios ^j   Tsapas, Apostolos G ^g   Tselepis, Alexandros D ^k   Tsioufis, Konstantinos ^h   Tziomalos, Konstantinos ^a   Tzotzas, Themistoklis ^l   Vasiliadis, Themistoklis G ^g   Vlachopoulos, Charalambos ^h   Mikhailidis, Dimitri P ^m   Mantzoros, Christos ⁿ   more..

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f UNIVERSITY OF IOANNINA   (Greece)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^j Athens Euroclinic   (Greece)

^k UNIVERSITY OF IOANNINA   (Greece)

^l St Luke's Hospital   (Greece)

^m ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁿ HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Ezetimibe; Hepatocellular cancer (HCC); Non alcoholic fatty liver disease (NAFLD); Non alcoholic steatohepatitis (NASH); Pioglitazone; Statins

Indexed keywords

ANTIDIABETIC AGENT; CASPASE; CENICRIVIROC; CRYOPYRIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA; NIVOCASAN; OBETICHOLIC ACID; PIOGLITAZONE; PROPROTEIN CONVERTASE 9; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

CARDIOVASCULAR RISK; ENZYME INHIBITION; GENE; GENETIC POLYMORPHISM; HUMAN; LIFESTYLE MODIFICATION; LIVER BIOPSY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PNPLA3 GENE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPLICATION; FATTY LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; NON-ALCOHOLIC FATTY LIVER DISEASE; THIAZOLIDINEDIONES;

EID: 85015044198     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2017.02.014     Document Type: Review

References (104)

1. [1] EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). J Hepatol, 64, 2016, 1388–1402.
2. [2] Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
3. [3] Fazel, Y., Koenig, A.B., Sayiner, M., Goodman, Z.D., Younossi, Z.M., Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 65 (2016), 1017–1025.
4. [4] Seto, W.K., Yuen, M.F., Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol 52 (2017), 164–174.
5. [5] Valenti, L., Bugianesi, E., Pajvani, U., Targher, G., Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver Int, 2016, 10.1111/liv.13185.
6. [6] Berlanga, A., Guiu-Jurado, E., Porras, J.A., Auguet, T., Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 7 (2014), 221–239.
7. [7] Buzzetti, E., Pinzani, M., Tsochatzis, E.A., The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65 (2016), 1038–1048.
8. [8] Polyzos, S.A., Kountouras, J., Deretzi, G., Zavos, C., Mantzoros, C.S., The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease. Curr Mol Med 12 (2012), 68–82.
9. [9] Polyzos, S.A., Kountouras, J., Mantzoros, C.S., Adipokines in nonalcoholic fatty liver disease. Metabolism 65 (2016), 1062–1079.
10. [10] Bechmann, L.P., Hannivoort, R.A., Gerken, G., Hotamisligil, G.S., Trauner, M., Canbay, A., The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56 (2012), 952–964.
11. [11] Marí, M., Caballero, F., Colell, A., Morales, A., Caballeria, J., Fernandez, A., et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4 (2006), 185–198.
12. [12] Polyzos, S.A., Kountouras, J., Zavos, C., Deretzi, G., Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46 (2012), 272–284.
13. [13] Kantartzis, K., Stefan, N., Cardiovascular disease in patients with non-alcoholic fatty liver disease. Ann Gastroenterol 25 (2012), 276–277.
14. [14] Romiopoulos, I., Kountouras, J., Polyzos, S.A., Zavos, C., Kapetanakis, N., Deretzi, G., et al. Helicobacter pylori-related metabolic syndrome might justify earlier colorectal cancer screening. Gastrointest Endosc 80 (2014), 188–189.
15. [15] Sanna, C., Rosso, C., Marietti, M., Bugianesi, E., Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci, 17, 2016 [pii: E717].
16. [16] Doycheva, I., Patel, N., Peterson, M., Loomba, R., Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications 27 (2013), 293–300.
17. [17] Kim, D., Kim, W.R., Kim, H.J., Therneau, T.M., Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
18. [18] Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G., Barbui, C., Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65 (2016), 589–600.
19. [19] VanWagner, L.B., Wilcox, J.E., Colangelo, L.A., Lloyd-Jones, D.M., Carr, J.J., Lima, J.A., et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 62 (2015), 773–783.
20. [20] VanWagner, L.B., Ning, H., Lewis, C.E., Shay, C.M., Wilkins, J., Carr, J.J., et al. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study. Atherosclerosis 235 (2014), 599–605.
21. [21] Pais, R., Giral, P., Khan, J.F., Rosenbaum, D., Housset, C., Poynard, T., et al., LIDO Study Group, Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol 65 (2016), 95–102.
22. [22] Fracanzani, A.L., Pisano, G., Consonni, D., Tiraboschi, S., Baragetti, A., Bertelli, C., et al. Epicardial adipose tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease. PLoS One, 11, 2016, e0162473.
23. [23] Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62:1 Suppl (2015), S47–S64.
24. [24] Alkhouri, N., Feldstein, A.E., Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet?. Metabolism 65 (2016), 1087–1095.
25. [25] Mencin, A.A., Loomba, R., Lavine, J.E., Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 12 (2015), 617–628.
26. [26] Rinella, M.E., Sanyal, A.J., Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol 13 (2016), 196–205.
27. [27] Hardy, T., Anstee, Q.M., Day, C.P., Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol 31 (2015), 175–183.
28. [28] He, L., Liu, X., Wang, L., Yang, Z., Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials. Medicine (Baltimore), 95, 2016, e494727.
29. [29] Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., Marchesini, G., A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53 (2010), 372–384.
30. [30] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
31. [31] Liao, H.W., Saver, J.L., Wu, Y.L., Chen, T.H., Lee, M., Ovbiagele, B., Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open, 7, 2017, e013927.
32. [32] Boettcher, E., Csako, G., Pucino, F., Wesley, R., Loomba, R., Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 35 (2012), 66–75.
33. [33] Spengler, E.K., Loomba, R., Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc 90 (2015), 1233–1246.
34. [34] Sahebkar, A., Chew, G.T., Watts, G.F., New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 15 (2014), 493–503.
35. [35] Okada, Y., Yamaguchi, K., Nakajima, T., Nishikawa, T., Jo, M., Mitsumoto, Y., et al. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int 33 (2013), 301–311.
36. [36] Ji, G., Zhao, X., Leng, L., Liu, P., Jiang, Z., Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. Lipids Health Dis 10 (2011), 23–32.
37. [37] Seif El-Din, S.H., El-Lakkany, N.M., El-Naggar, A.A., Hammam, O.A., Abd El-Latif, H.A., Ain-Shoka, A.A., et al. Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats. Res Pharm Sci 10 (2015), 275–287.
38. [38] Kabel, A.M., Abd Elmaaboud, M.A., Albarraq, A.A., Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis. Prostaglandins Leukot Essent Fat Acids 96 (2015), 1–9.
39. [39] Matafome, P., Louro, T., Rodrigues, L., Crisóstomo, J., Nunes, E., Amaral, C., et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 27 (2011), 54–62.
40. [40] Vilà, L., Rebollo, A., Ađalsteisson, G.S., Alegret, M., Merlos, M., Roglans, N., et al. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol 251 (2011), 32–40.
41. [41] Chong, L.W., Hsu, Y.C., Lee, T.F., Lin, Y., Chiu, Y.T., Yang, K.C., et al. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol, 15, 2015, 22.
42. [42] Miyaki, T., Nojiri, S., Shinkai, N., Kusakabe, A., Matsuura, K., Iio, E., et al. Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. Hepatol Res 41 (2011), 375–385.
43. [43] Athyros, V.G., Tziomalos, K., Gossios, T.D., Griva, T., Anagnostis, P., Kargiotis, K., et al., GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet 376 (2010), 1916–1922.
44. [44] Tikkanen, M.J., Fayyad, R., Faergeman, O., Olsson, A.G., Wun, C.C., Laskey, R., et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 168 (2013), 3846–3852.
45. [45] Athyros, V.G., Katsiki, N., Mikhailidis, D.P., Statins and non-alcoholic steatohepatitis. Metabolism 66 (2017), e1–e2.
46. [46] Athyros, V.G., Katsiki, N., Karagiannis, A., Mikhailidis, D.P., Are statins ‘IDEAL’ for non-alcoholic fatty liver disease?. Curr Med Res Opin 30 (2014), 229–231.
47. [47] Tziomalos, K., Athyros, V.G., Karagiannis, A., Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 10 (2012), 162–172.
48. [48] Vlachopoulos, C., Manesis, E., Baou, K., Papatheodoridis, G., Koskinas, J., Tiniakos, D., et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study. Am J Hypertens 23 (2010), 1183–1189.
49. [49] Athyros, V.G., Ganotakis, E., Kolovou, G.D., Nicolaou, V., Achimastos, A., Bilianou, E., et al. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 9 (2011), 647–657.
50. [50] Athyros, V.G., Mikhailidis, D.P., Didangelos, T.P., Giouleme, O.I., Liberopoulos, E.N., Karagiannis, A., et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 22 (2006), 873–883.
51. [51] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397.
52. [52] Lonardo, A., Sookoian, S., Pirola, C.J., Targher, G., Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 65 (2016), 1136–1150.
53. [53] Rallidis, L.S., Drakoulis, C.K., Parasi, A.S., Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 174 (2004), 193–196.
54. [54] Hyogo, H., Tazuma, S., Arihiro, K., Iwamoto, K., Nabeshima, Y., Inoue, M., et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 57 (2008), 1711–1718.
55. [55] Kargiotis, K., Katsiki, N., Athyros, V.G., Giouleme, O., Patsiaoura, K., Katsiki, E., et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 12 (2014), 505–511.
56. [56] Kargiotis, K., Athyros, V.G., Giouleme, O., Katsiki, N., Katsiki, E., Anagnostis, P., et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 21 (2015), 7860–7868.
57. [57] Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R.M., Pipitone, R., Karja, V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 63 (2015), 705–712.
58. [58] Mintziori, G., Polyzos, S.A., Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother 17 (2016), 1937–1946.
59. [59] Sookoian, S., Pirola, C.J., Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53 (2011), 1883–1894.
60. [60] Nascimbeni, F., Aron-Wisnewsky, J., Pais, R., Tordjman, J., Poitou, C., Charlotte, F., et al., LIDO study Group, Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol, 3, 2016, e000075.
61. [61] Eslami, L., Merat, S., Malekzadeh, R., Nasseri-Moghaddam, S., Aramin, H., Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev, 2013, CD008623.
62. [62] Singh, S., Singh, P.P., Singh, A.G., Murad, M.H., Sanchez, W., Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144 (2013), 323–332.
63. [63] Simon, T.G., Bonilla, H., Yan, P., Chung, R.T., Butt, A.A., Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology 64 (2016), 47–57.
64. [64] Kim, G., Jang, S.Y., Han, E., Lee, Y.H., Park, S.Y., Nam, C.M., et al. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: a nationwide nested case–control study. Int J Cancer 140 (2017), 798–806.
65. [65] Polyzos, S.A., Kountouras, J., Anastasilakis, A.D., Geladari, E.V., Mantzoros, C.S., Irisin in patients with nonalcoholic fatty liver disease. Metabolism 63 (2014), 207–217.
66. [66] Polyzos, S.A., Kountouras, J., Polymerou, V., Papadimitriou, K.G., Zavos, C., Katsinelos, P., Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease. Ann Hepatol 15 (2016), 705–714.
67. [67] Cabrera, D., Ruiz, A., Cabello-Verrugio, C., Brandan, E., Estrada, L., Pizarro, M., et al. Diet-induced nonalcoholic fatty liver disease is associated with sarcopenia and decreased serum insulin-like growth factor-1. Dig Dis Sci 61 (2016), 3190–3198.
68. [68] Deushi, M., Osaka, M., Nakano, K., Osada, K., Egashira, K., Yoshida, M., Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates. FEBS Open Bio 6 (2016), 1008–1015.
69. [69] Lee, D.H., Han, D.H., Nam, K.T., Park, J.S., Kim, S.H., Lee, M., Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radic Biol Med 99 (2016), 520–532.
70. [70] Simon, T.G., Corey, K.E., Chung, R.T., Giugliano, R., Cardiovascular risk reduction in patients with nonalcoholic fatty liver disease: the potential role of ezetimibe. Dig Dis Sci 61 (2016), 3425–3435.
71. [71] Takeshita, Y., Takamura, T., Honda, M., Kita, Y., Zen, Y., Kato, K., et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 57 (2014), 878–890.
72. [72] Filippatos, T.D., Elisaf, M.S., Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol 3 (2011), 265–267.
73. [73] Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65 (2016), 1109–1123.
74. [74] Lin, S.C., Ang, B., Hernandez, C., Bettencourt, R., Jain, R., Salotti, J., et al. Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. Therap Adv Gastroenterol 9 (2016), 152–161.
75. [75] Loomba, R., Sirlin, C.B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61 (2015), 1239–1250.
76. [76] Averna, M., The effect of ezetimibe on NAFLD. Atheroscler Suppl 17 (2015), 27–34.
77. [77] Ruscica, M., Ferri, N., Macchi, C., Meroni, M., Lanti, C., Ricci, C., et al. Liver fat accumulation is associated with circulating PCSK9. Ann Med 48 (2016), 384–391.
78. [78] Ruscica, M., Ricci, C., Macchi, C., Magni, P., Cristofani, R., Liu, J., et al. Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J Biol Chem 291 (2016), 3508–3519.
79. [79] Zhu, X., Bian, H., Gao, X., The potential mechanisms of berberine in the treatment of nonalcoholic fatty liver disease. Molecules, 21, 2016 [pii: E1336].
80. [80] Anstee, Q.M., Concas, D., Kudo, H., Levene, A., Pollard, J., Charlton, P., et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 53 (2010), 542–550.
81. [81] Ratziu, V., Sheikh, M.Y., Sanyal, A.J., Lim, J.K., Conjeevaram, H., Chalasani, N., et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 55 (2012), 419–428.
82. [82] Makri, E., Cholongitas, E., Tziomalos, K., Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol 22 (2016), 9039–9043.
83. [83] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., et al., NASH Clinical Research Network, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
84. [84] Honda, Y., Imajo, K., Kato, T., Kessoku, T., Ogawa, Y., Tomeno, W., et al. The selective SGLT2 inhibitor Ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One, 11, 2016, e0146337.
85. [85] Jojima, T., Tomotsune, T., Iijima, T., Akimoto, K., Suzuki, K., Aso, Y., Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr, 8, 2016, 45.
86. [86] Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
87. [87] Smits, M.M., Tonneijck, L., Muskiet, M.H., Kramer, M.H., Pouwels, P.J., Pieters-van den Bos, I.C., et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia 59 (2016), 2588–2593.
88. [88] Tang, A., Rabasa-Lhoret, R., Castel, H., Wartelle-Bladou, C., Gilbert, G., Massicotte-Tisluck, K., et al. Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial. Diabetes Care 38 (2015), 1339–1346.
89. [89] Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol, 2017 [pii: S2210-7401(16)30202-9].
90. [90] Wree, A., McGeough, M.D., Peña, C.A., Schlattjan, M., Li, H., Inzaugarat, M.E., et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berl) 92 (2014), 1069–1082.
91. [91] Barreyro, F.J., Holod, S., Finocchietto, P.V., Camino, A.M., Aquino, J.B., Avagnina, A., et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int 35 (2015), 953–966.
92. [92] Wan, X., Xu, C., Yu, C., Li, Y., Role of NLRP3 inflammasome in the progression of NAFLD to NASH. Can J Gastroenterol Hepatol, 2016, 2016, 6489012.
93. [93] Tilg, H., Moschen, A.R., Zsabo, G., IL-1 cytokine family members and various inflammasomes mediate different aspects of both ALD and NAFLD. Hepatology 64 (2016), 955–965.
94. [94] Suzuki, I., Yamauchi, T., Onuma, M., Nozaki, S., Allopurinol, an inhibitor of uric acid synthesis-can it be used for the treatment of metabolic syndrome and related disorders?. Drugs Today (Barc) 45 (2009), 363–378.
95. [95] Cai, W., Wu, X., Zhang, B., Miao, L., Sun, Y.P., Zou, Y., et al. Serum uric acid levels and non-alcoholic fatty liver disease in Uyghur and Han ethnic groups in northwestern China. Arq Bras Endocrinol Metabol 57 (2013), 617–622.
96. [96] Salameh, H., Hanayneh, M.A., Masadeh, M., Naseemuddin, M., Matin, T., Erwin, A., et al. PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum. J Clin Transl Hepatol 4 (2016), 175–191.
97. [97] Friedman, S., Sanyal, A., Goodman, Z., Lefebvre, E., Gottwald, M., Fischer, L., et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR phase 2b study design. Contemp Clin Trials 47 (2016), 356–365.
98. [98] Liu, X.L., Cao, H.X., Fan, J.G., MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease. J Dig Dis 17 (2016), 708–715.
99. [99] Di Mauro, S., Ragusa, M., Urbano, F., Filippello, A., Di Pino, A., Scamporrino, A., et al. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: clinical implications. Nutr Metab Cardiovasc Dis 26 (2016), 1129–1139.
100. [100] Mahgoub, A., Steer, C.J., MicroRNAs in the evaluation and potential treatment of liver diseases. J Clin Med, 5, 2016 [pii: E52. doi: 10.3390/jcm5050052].
101. [101] Bader, T., Yes! Statins can be given to liver patients. J Hepatol 56 (2012), 305–307.
102. [102] Targher, G., Day, C.P., Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
103. [103] Del Ben, M., Baratta, F., Polimeni, L., et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 27 (2017), 161–167.
104. [104] Authors/Task Force Members:Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J., Drexel, H., et al. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253 (2016), 281–344.